Malta - Engels - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - imipramine hydrochloride - coated tablet - imipramine hydrochloride 25 mg - psychoanaleptics

Australië - Engels - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - imipramine hydrochloride, quantity: 10 mg - tablet, sugar coated - excipient ingredients: macrogol 8000; povidone; stearic acid; hypromellose; purified talc; glycerol; magnesium stearate; titanium dioxide; maize starch; microcrystalline cellulose; iron oxide red; colloidal anhydrous silica; lactose monohydrate; sucrose; copovidone - major depression. nocturnal enuresis (from the age of 5 years onwards and provided the possibility of organic causes has first been excluded).

Australië - Engels - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - imipramine hydrochloride, quantity: 25 mg - tablet, sugar coated - excipient ingredients: titanium dioxide; microcrystalline cellulose; colloidal anhydrous silica; sucrose; magnesium stearate; stearic acid; lactose monohydrate; hypromellose; maize starch; glycerol; povidone; iron oxide red; macrogol 8000; carnauba wax; purified talc; copovidone - major depression. nocturnal enuresis (from the age of 5 years onwards and provided the possibility of organic causes has first been excluded).

Malta - Engels - Medicines Authority

crescent pharma international limited 260, triq san albert, gzira gzr 1150, malta - imipramine hydrochloride - coated tablet - imipramine hydrochloride 10 mg - psychoanaleptics

Malta - Engels - Medicines Authority

crescent pharma international limited 260, triq san albert, gzira gzr 1150, malta - imipramine hydrochloride - coated tablet - imipramine hydrochloride 25 mg - psychoanaleptics

Canada - Engels - Health Canada

aa pharma inc - imipramine hydrochloride - tablet - 25mg - imipramine hydrochloride 25mg - tricyclics and other norepinephrine-reuptake inhibitors

Canada - Engels - Health Canada

aa pharma inc - imipramine hydrochloride - tablet - 50mg - imipramine hydrochloride 50mg - tricyclics and other norepinephrine-reuptake inhibitors

Canada - Engels - Health Canada

aa pharma inc - imipramine hydrochloride - tablet - 10mg - imipramine hydrochloride 10mg - tricyclics and other norepinephrine-reuptake inhibitors

Canada - Engels - Health Canada

aa pharma inc - imipramine hydrochloride - tablet - 75mg - imipramine hydrochloride 75mg - tricyclics and other norepinephrine-reuptake inhibitors

Verenigde Staten - Engels - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - imipramine hydrochloride (unii: bke5q1j60u) (imipramine - unii:ogg85sx4e4) - imipramine hydrochloride 10 mg - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. may be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests. in patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. the effectiveness of treatment may decrease with continued drug administration. the concomitant use of monoamine oxidase inhibiting compounds is contraindicated. hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. the potentiation of adverse effects can be serious, or even fatal. when it is desired to substitute imipramine hydrochloride tablets in patients receiving a monoamine oxidase inhibitor, as long an interval should elapse as the clinical situation will allow, with a minimum of 14 days. initial dosage should be low and increases should be gradual and cautiously prescribed. the drug is contraindicated during the acute recovery period after a myocardial infarction. patients with a known hypersensitivity to this compound should not be given the drug. the possibility of cross-sensitivity to other dibenzazepine compounds should be kept in mind.